Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6% - Time to Sell?

Key Points

• Capricor Therapeutics shares fell 6% to about $8.91, with trading volume 44% below the stock’s average daily volume.
• Analyst sentiment has weakened, with several firms downgrading the stock to neutral or hold and price targets near $7. MarketBeat’s consensus rating is Hold, despite an average price target of $30.25.
• The company reported a quarterly loss of $0.70 per share, missing the $0.59 consensus estimate; analysts expect a full-year loss of $1.71 per share.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) shares fell 6% during trading on Thursday. The company traded as low as $8.91 and last traded at $8.9050. 1,753,203 shares changed hands during trading, a decline of 44% from the average daily volume of 3,128,219 shares. The stock had previously closed at $9.47.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Capricor Therapeutics in a report on Friday, September 11th. Roth Capital lowered shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 target price on the stock. in a report on Monday, July 27th. Wall Street Zen cut shares of Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. JonesTrading cut Capricor Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, July 31st. Finally, Alliance Global Partners cut shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 price objective on the stock. in a research report on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Capricor Therapeutics presently has a consensus rating of "Hold" and an average price target of $30.25.

Capricor Therapeutics Stock Performance

The firm has a market cap of $525.35 million, a price-to-earnings ratio of -3.72 and a beta of 0.72. The stock has a 50-day moving average of $7.96 and a 200-day moving average of $21.35.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CAPR. KBC Group NV acquired a new position in shares of Capricor Therapeutics during the 1st quarter worth about $44,000. ACT Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at approximately $43,000. Quantinno Capital Management LP grew its stake in Capricor Therapeutics by 16.8% in the first quarter. Quantinno Capital Management LP now owns 14,472 shares of the biotechnology company's stock valued at $440,000 after purchasing an additional 2,083 shares in the last quarter. Glenmede Trust Co. NA grew its stake in Capricor Therapeutics by 13.2% in the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company's stock valued at $1,104,000 after purchasing an additional 4,240 shares in the last quarter. Finally, Sei Investments Co. increased its position in shares of Capricor Therapeutics by 41.2% during the 1st quarter. Sei Investments Co. now owns 17,805 shares of the biotechnology company's stock worth $541,000 after purchasing an additional 5,195 shares during the last quarter. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company's programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.